litlas
ログインアカウント作成

David Lebwohl

1987–2025 年に発表

39
論文数
26,254
被引用数
36
h 指数
39
i10 指数

被引用数

David Lebwohl の年別被引用数1987 年: 被引用 9 件1988 年: 被引用 43 件1989 年: 被引用 42 件1990 年: 被引用 25 件1991 年: 被引用 28 件1992 年: 被引用 16 件1993 年: 被引用 11 件1994 年: 被引用 10 件1995 年: 被引用 12 件1996 年: 被引用 16 件1997 年: 被引用 12 件1998 年: 被引用 14 件1999 年: 被引用 16 件2000 年: 被引用 18 件2001 年: 被引用 11 件2002 年: 被引用 13 件2003 年: 被引用 20 件2004 年: 被引用 27 件2005 年: 被引用 50 件2006 年: 被引用 44 件2007 年: 被引用 66 件2008 年: 被引用 70 件2009 年: 被引用 133 件2010 年: 被引用 133 件2011 年: 被引用 194 件2012 年: 被引用 217 件2013 年: 被引用 310 件2014 年: 被引用 288 件2015 年: 被引用 242 件2016 年: 被引用 240 件2017 年: 被引用 205 件2018 年: 被引用 257 件2019 年: 被引用 816 件2020 年: 被引用 878 件2021 年: 被引用 874 件2022 年: 被引用 825 件2023 年: 被引用 644 件2024 年: 被引用 972 件2025 年: 被引用 516 件2026 年: 被引用 28 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,766 件、この内訳の 30.1%中国: 引用元論文 1,057 件、この内訳の 8.5%ドイツ: 引用元論文 787 件、この内訳の 6.3%イギリス: 引用元論文 732 件、この内訳の 5.9%イタリア: 引用元論文 716 件、この内訳の 5.7%フランス: 引用元論文 583 件、この内訳の 4.7%スペイン: 引用元論文 442 件、この内訳の 3.5%カナダ: 引用元論文 401 件、この内訳の 3.2%オランダ: 引用元論文 342 件、この内訳の 2.7%日本: 引用元論文 339 件、この内訳の 2.7%スイス: 引用元論文 333 件、この内訳の 2.7%オーストラリア: 引用元論文 266 件、この内訳の 2.1%
0%30.1%その他 21.9%

機関

分野

  • Medicine68.6%
  • Biochemistry, Genetics and Molecular Biology26.9%
  • Immunology and Microbiology2.1%
  • Materials Science0.4%
  • Chemistry0.3%
  • Engineering0.3%
  • その他1.4%

トピック

  • CAR-T cell therapy research11.3%
  • Virus-based gene therapy research4%
  • PI3K/AKT/mTOR signaling in cancer3.1%
  • Neuroendocrine Tumor Research Advances2.7%
  • CRISPR and Genetic Engineering2.7%
  • Nanowire Synthesis and Applications2.3%
  • その他73.9%

共著者

全論文

検索で開く
  1. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    著者: Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R. Verneris, Heather E. Stefanski, Gary D. Myers, Muna Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta Schlis, Kara L. Davis, Paul L. Martin, Eneida R. Nemecek, Gregory A. Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Françoise Méchinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia A. Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp - New England Journal of Medicine 2018 被引用: 5,641

  2. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis

    著者: Julian D. Gillmore, Ed Gane, Jörg Täubel, Justin Kao, Marianna Fontana, Michael L. Maitland, Jessica Seitzer, Daniel O’Connell, Kathryn Walsh, Kristy Wood, Jonathan D. Phillips, Yuanxin Xu, Adam Amaral, Adam P. Boyd, Jeffrey Cehelsky, Mark D. McKee, Andrew Schiermeier, Olivier Harari, Andrew Murphy, Christos A. Kyratsous, Brian Zambrowicz, Randy Soltys, David E. Gutstein, John P. Leonard, Laura Sepp‐Lorenzino, David Lebwohl - New England Journal of Medicine 2021 被引用: 1,633

  3. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    著者: José Baselga, Mario Campone, Martine Piccart, Howard A. Burris, Hope S. Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, Yoshinori Ito, Denise A. Yardley, Ines Deleu, Alejandra Perez, Thomas Bachelot, Luc Vittori, Zhiying Xu, Pabak Mukhopadhyay, David Lebwohl, Gabriel N. Hortobágyi - New England Journal of Medicine 2011 被引用: 2,828

  4. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

    著者: Hilary Longhurst, Karen Lindsay, Remy S. Petersen, Lauré M. Fijen, Padmalal Gurugama, David Maag, James S. Butler, Mrinal Y. Shah, A. Golden, Yuanxin Xu, Carri Boiselle, Joseph D Vogel, Ahmed M. Abdelhady, Michael L. Maitland, Mark D. McKee, Jessica Seitzer, Bo Han, Samantha Soukamneuth, John P. Leonard, Laura Sepp‐Lorenzino, Eliana D Clark, David Lebwohl, Danny M. Cohn - New England Journal of Medicine 2024 被引用: 166

  5. Everolimus for Advanced Pancreatic Neuroendocrine Tumors

    著者: James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg - New England Journal of Medicine 2011 被引用: 2,848

  6. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    著者: Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud - The Lancet 2008 被引用: 3,012

  7. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

    著者: Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, José Baselga, Michael Gnant, Gabriel N. Hortobágyi, Mario Campone, Barbara Pistilli, Martine Piccart, Bohuslav Melichar, Katarína Petráková, Francis P. Arena, Frans Erdkamp, Wael A. Harb, Wentao Feng, Ayelet Cahana, Tetiana Taran, David Lebwohl, Hope S. Rugo - Advances in Therapy 2013 被引用: 520

  8. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    著者: Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao - The Lancet 2011 被引用: 1,052

  9. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy

    著者: Marianna Fontana, Scott D. Solomon, Jessica Kachadourian, Liron Walsh, Ricardo Rocha, David Lebwohl, Derek K. Smith, Jörg Täubel, Edward Gane, Björn Pilebro, David J. Adams, Yousuf Razvi, Joy Olbertz, Alexandra Haagensen, Peijuan Zhu, Yuanxin Xu, Adia Leung, Alison Sonderfan, David E. Gutstein, Julian D. Gillmore - New England Journal of Medicine 2024 被引用: 113

  10. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

    著者: John J. Bissler, J.C. Kingswood, Elżbieta Radzikowska, Bernard A. Zonnenberg, Michael Frost, Е. Д. Белоусова, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J. de Vries, Vicky Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budde - The Lancet 2013 被引用: 879

  11. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

    著者: David Neal Franz, Е. Д. Белоусова, Steven Sparagana, E. Martina Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael Kohrman, J. Robert Flamini, Joyce Y. Wu, Paolo Curatolo, Petrus J. de Vries, Vicky Whittemore, Elizabeth A. Thiele, James Ford, Gaurav Shah, Helene Cauwel, David Lebwohl, Tarek Sahmoud, Sergiusz Jóźwiak - The Lancet 2012 被引用: 784

  12. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

    著者: Gabriel N. Hortobágyi, David Chen, Martine Piccart, Hope S. Rugo, Howard A. Burris, Kathleen I. Pritchard, Mario Campone, Shinzaburo Noguchi, Alejandra Perez, Ines Deleu, Mikhail Shtivelband, Norikazu Masuda, Shaker R. Dakhil, Ian C. Anderson, Douglas Robinson, Wei He, Abhishek D. Garg, E. Robert McDonald, Hans Bitter, Alan Huang, Tetiana Taran, Thomas Bachelot, Fabienne Lebrun, David Lebwohl, José Baselga - Journal of Clinical Oncology 2015 被引用: 246

  13. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update

    著者: David Lebwohl, Renzo Canetta - European Journal of Cancer 1998 被引用: 752

  14. CRISPR-Based Therapy for Hereditary Angioedema

    著者: Danny M. Cohn, Padmalal Gurugama, Markus Magerl, Constance H. Katelaris, David Launay, Laurence Bouillet, Remy S. Petersen, Karen Lindsay, Emel Aygören‐Pürsün, David Maag, James S. Butler, Mrinal Y. Shah, A. Golden, Yuanxin Xu, Ahmed M. Abdelhady, David Lebwohl, Hilary Longhurst - New England Journal of Medicine 2024 被引用: 52

  15. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

    著者: Richard M. Stone, Daniel J. DeAngelo, Virginia M. Klimek, Ilene Galinsky, Eli Estey, Stephen D. Nimer, Wilson Grandin, David Lebwohl, Yanfeng Wang, Pamela Cohen, Edward A. Fox, Donna Neuberg, Jennifer Clark, D. Gary Gilliland, James D. Griffin - Blood 2004 被引用: 660

  16. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

    著者: Atsushi Ohtsu, Jaffer A. Ajani, Yu-Xian Bai, Yung‐Jue Bang, Hyun Cheol Chung, Hong-Ming Pan, Tarek Sahmoud, Lin Shen, Kun‐Huei Yeh, Keisho Chìn, Kei Muro, Yeul Hong Kim, David Ferry, Niall C. Tebbutt, Salah‐Eddin Al‐Batran, Heind Smith, Chiara Costantini, Syed Rizvi, David Lebwohl, Eric Van Cutsem - Journal of Clinical Oncology 2013 被引用: 494

  17. Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2

    著者: Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, Shantha Rao, Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard - JNCI Journal of the National Cancer Institute 2013 被引用: 98

  18. Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma

    著者: J. Randolph Hecht, Tanja Trarbach, John D. Hainsworth, Pierre Major, Elke Jäger, Robert A. Wolff, Katherine Lloyd-Salvant, G. Bodoky, Kelly Pendergrass, William J. Berg, Bee-Lian Chen, T. Jalava, Gerold Meinhardt, Dirk Laurent, David Lebwohl, David J. Kerr - Journal of Clinical Oncology 2011 被引用: 175

  19. Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

    著者: Michael I. Koukourakis, Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C. Gatter, Tanja Trarbach, Gunnar Folprecht, Michael Shi, David Lebwohl, T. Jalava, Dirk Laurent, Gerold Meinhardt, Adrian L. Harris - Clinical Cancer Research 2011 被引用: 131

  20. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

    著者: James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, J. Peter, T Haas, David Lebwohl, Eric Van Cutsem, Matthew H. Kulke, Timothy J. Hobday, Thomas M. O’Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James Posey, Bertram Wiedenmann - Journal of Clinical Oncology 2009 被引用: 649

  21. Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

    著者: Josep Tabernero, Federico Rojo, Emiliano Calvo, Howard A. Burris, Ian Judson, Katharine Hazell, Erika Martinelli, Santiago Ramón y Cajal, Suzanne F. Jones, Laura Vidal, Nicholas Shand, Teresa Macarulla, Francisco Javier Ramos, Saša Dimitrijević, Ulrike Zoellner, Pui Tang, Michael Stumm, Heidi A. Lane, David Lebwohl, José Baselga - Journal of Clinical Oncology 2008 被引用: 532

  22. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

    著者: Ruirong Yuan, Andrea Kay, William J. Berg, David Lebwohl - Journal of Hematology & Oncology 2009 被引用: 250

  23. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

    著者: David Lebwohl, Özlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, T Haas, Joseph A. Posluszny, Stephen Saletan, William J. Berg - Annals of the New York Academy of Sciences 2013 被引用: 91

  24. Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

    著者: Stacie Ittershagen, Solveig G. Ericson, Lamis Eldjerou, Ali Shojaee, Eric Bleickardt, Manisha Patel, Tetiana Taran, Oezlem Anak, Charlene Hall, Mimi Leung, Deborah Roccoberton, Florence Salmon, Miriam Fuchs, Vadim Romanov, David Lebwohl - Current Hematologic Malignancy Reports 2019 被引用: 17